Mammary Cell News 9.39 October 5, 2017 | |
| |
TOP STORYResearchers demonstrated that MYC and MCL1 cooperate in the maintenance of chemotherapy-resistant cancer stem cells (CSCs) in triple-negative breast cancer. MYC and MCL1 increased mitochondrial oxidative phosphorylation and the generation of reactive oxygen species, processes involved in maintenance of CSCs. [Cell Metab] Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Investigators showed that extracellular matrix stiffness leads to mechano-signal transduction in mesenchymal stem cells (MSCs) which promotes mammary tumor growth in part through secretion of the signaling protein prosaposin. On a stiff matrix, MSC cultured with conditioned media from mammary cancer cells expressed increased levels of alpha-smooth muscle actin, a marker of cancer-associated fibroblasts, compared to MSC cultured on a soft matrix. [Cancer Res] Abstract Researchers profiled a collection of GLI antagonists possessing distinct mechanisms of action for efficacy in phenotypic models of inflammatory and non-inflammatory breast cancer (IBC and non-IBC) that they showed expressed varying levels of Hedgehog pathway mediators. Compounds GANT61, HPI-1, and JK184 decreased cell proliferation, inhibited GLI1 mRNA expression and decreased the number of colonies formed in the TN-IBC (SUM149) and TNBC cell lines (MDA-MB-231 and SUM159). [Cancer Lett] Abstract The authors reported a genome-wide association study that identified common SNPs near the CTSO gene and in ZNF423 associated with development of breast cancer during tamoxifen therapy in the NSABP P-1 and P-2 breast cancer prevention trials. They investigated their roles in estrogen receptor α (ERα)-positive breast cancer growth and tamoxifen response, focusing on the mechanism of CTSO. [PLoS Genet] Full Article Scientists tested the involvement of the endocytic adaptor protein endophilin A2 (Endo II) in human epidermal growth factor receptor-2 (HER2+) breast cancer models, and their responses to treatments with trastuzumab and trastuzumab-emtansine. High Endo II protein expression was detected in HER2-positive tumors, and was linked to worse overall survival in node-positive HER2+ breast cancers at the mRNA level. [Breast Cancer Res] Full Article Scientists found that Kdm3a was expressed in mouse mammary gland epithelial cells. Knockout of Kdm3a significantly increased H3K9me2/me1 levels in these epithelial cells, which correlated with markedly decreased mammary gland ductal elongation and branching in the intact knockout virgin mice. [Oncotarget] Full Article The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence The authors identified a novel lncRNA, BMP/OP-Responsive Gene (BORG), whose expression directly correlates with aggressive breast cancer phenotypes, as well as with metastatic competence and disease recurrence in multiple clinical cohorts. [Sci Rep] Full Article Investigators evaluated the combined effects of ZEA and AFB1 on cell growth and cell cycle progression, using a human breast cancer cell line MCF-7. Their results showed that ZEA and AFB1 produced significant interactive effects on cell growth, DNA synthesis and cell cycle progression. [Toxicol Lett] Abstract Dysregulation of POPDC1 Promotes Breast Cancer Cell Migration and Proliferation Researchers assessed the potential of Popeye domain-containing protein 1 (POPDC1) as a novel target for inhibiting breast cancer cell migration and proliferation. POPDC1 was significantly suppressed with reduced cell membrane localization in breast cancer cells. [Biosci Rep] Abstract | |
| |
REVIEWSThe Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas The authors recapitulate the main endogenous molecular signals involved in this process, and their cross-talk with paracrine factors. These signals and cross-talk include the extracellular matrix; the secretome of cancer-associated fibroblasts, macrophages, cancer stem cells, and cancer cells; and exosomes with their cargo of miRNAs. [Cancers (Basel)] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSThe Breast Cancer Research Foundation Commits $59.5 Million to Fund Cancer Research Worldwide The Breast Cancer Research Foundation announced a $59.5 million commitment to breast cancer research for 2017-2018. Its largest investment to date, the grants will support the work of more than 275 scientists at leading academic and medical institutions in 15 countries. [Breast Cancer Research Foundation] Press Release Genentech, announced the FDA has accepted the company’s supplemental Biologics License Application and granted Priority Review for Perjeta®, in combination with Herceptin® (trastuzumab) and chemotherapy, for adjuvant treatment of HER2-positive early breast cancer. [Genentech, Inc.] Press Release Lilly Receives U.S. FDA Approval of Verzenioâ„¢ (Abemaciclib) Eli Lilly and Company announced that the FDA has approved Verzenioâ„¢ (abemaciclib) in combination with fulvestrant for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced or metastatic breast cancer with disease progression following endocrine therapy, and as monotherapy for the treatment of adult patients with HR+, HER2– advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. [Eli Lilly and Company] Press Release Two widely respected and accomplished breast cancer investigators join the ranks of an esteemed group of scientists as recipients of this year’s Brinker Awards – the highest scientific honor awarded by Susan G. Komen, the world’s leading breast cancer organization. [Susan G Komen] Press Release | |
| |
POLICY NEWSDoes Your State Get Its Fair Share of Federal Research Dollars? The only physicist in Congress has introduced a bill that could rekindle a debate over how to deal with geographic disparities in the allocation of federal research funding. [ScienceInsider] Editorial Scientists Plead with Brazilian Government to Restore Funding Anxiety is growing in Brazil over the country’s collapsing research budgets. President Michel Temer had slashed funding for science by 44% in March and has proposed additional decreases for 2018 — even as some science institutes run out of money for basic needs, such as paying electricity bills. The 2017 science budget, at 3.2 billion reais (US$1 billion), is the lowest the country has seen in at least 12 years. [Nature News] Editorial Judge Recommends Ruling to Block Internet Access to Sci-Hub The American Chemical Society (ACS) brought a case against Sci-Hub, a pirate site providing access to scientific articles, for copyright and trademark infringement. Following a hearing at a court in Virginia, Magistrate Judge John Anderson filed a report that recommended ruling in favor of ACS on all counts. [The Scientist] Editorial After Upheaval, Russian Academy of Sciences Gets New Leader After months of uncertainty, the Russian Academy of Sciences here finally has a new leader. Russian President Vladimir Putin approved physicist Alexander Sergeyev as the academy’s president for the next 5 years. Sergeyev has vowed to secure more money for Russian science and create a fund, through a new tax on fossil fuel company profits, for upgrading the country’s antiquated research infrastructure. [ScienceInsider] Editorial
| |
EVENTSNEW 14th Annual Stem Cell Symposium: Technology Innovation for Stem Cell Research and Therapy Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellowship – Breast Cancer Research (Geisel School of Medicine at Dartmouth) NEW Assistant Professor – Cancer Biology (Perelman School of Medicine) NEW Assistant Professor – Cancer Research (University of Minnesota) NEW Postdoctoral Position – Cancer Metabolism (University of Louvain) Postdoctoral Position – Transcriptomics and Cancer Epigenetics (Universität Basel) Higher Scientific Officer – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Training Fellow – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Opportunities – Cancer Research (Albert Einstein College of Medicine in New York) Associate Medical Director/Medical Director – Breast Cancer (Genentech, Inc.) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|